Why Do People with LOW Cholesterol Seem to Be at HIGHER Risk? The Truth Behind the Paradox

You may have heard that very low cholesterol is linked to higher mortality, which can sound worrying at first. However, this association comes from misinterpreted observational data, not a true cause-and-effect relationship.

In many studies, the higher mortality seen in people with low cholesterol is explained by confounding factors, especially reverse causation: serious illnesses (such as cancer, chronic infections, or frailty) can themselves lower cholesterol levels. In other words, low cholesterol is often a result of illness, not its cause.

When these factors are accounted for, the broader evidence shows that elevated LDL cholesterol is a well-established causal risk factor for cardiovascular disease, while lowering it (for example through diet or medication when indicated) reduces cardiovascular risk.

In short, the so-called “paradox” arises from misinterpreting observational data. It does not contradict the biological role of cholesterol or the strong clinical evidence linking high LDL cholesterol to cardiovascular risk. Context is crucial: low cholesterol often reflects underlying illness rather than causing harm itself.

---

Cholesterol: More Than Just a Number

Before exploring the apparent paradox between low cholesterol and mortality, it helps to understand what cholesterol actually is and what it does in the body.

Although it is often portrayed mainly as a cardiovascular risk factor, this is a simplified view. Cholesterol is in fact an essential biological molecule with multiple fundamental roles in human physiology.

What is Cholesterol?

Cholesterol is a lipid molecule, a type of fat, that is absolutely indispensable for the correct functioning of your body. It is not inherently harmful. In fact, without cholesterol, you could not survive. Here is a brief overview of its essential biological roles:

1. Cell Membrane Structure Cholesterol is a fundamental structural component of every cell membrane in the human body. It regulates membrane fluidity, ensures that cells maintain their integrity and shape, and controls the movement of substances in and out of cells. Without adequate cholesterol, cell membranes become dangerously unstable.

2. Precursor to Vital Hormones Cholesterol serves as the raw material, the biochemical precursor, for the synthesis of a wide range of steroid hormones. These include:

• Estrogens: the primary female sex hormones, essential for reproductive health, bone density, and cardiovascular protection in women.
• Testosterone: the primary male sex hormone, critical for muscle mass, libido, mood, and overall metabolic health.
• Cortisol: a glucocorticoid hormone produced by the adrenal glands that regulates the stress response, immune function, blood sugar, and anti-inflammatory processes.
• Aldosterone: which regulates sodium balance and blood pressure.

Without sufficient cholesterol, the body cannot produce these hormones in adequate quantities, leading to potentially serious hormonal deficiencies.

3. Vitamin D Synthesis Cholesterol is the direct precursor to vitamin D, the hormone-like vitamin that is synthesized in the skin upon exposure to ultraviolet (UV) radiation from sunlight. Vitamin D is critical for calcium absorption, bone health, immune function, and has been linked to reduced risk of numerous chronic diseases. People with very low cholesterol may have impaired capacity to synthesize vitamin D.

4. Bile Acid Production The liver converts cholesterol into bile acids, which are essential for the digestion and absorption of dietary fats and fat-soluble vitamins (A, D, E, and K) in the small intestine. Without adequate bile production, nutrient absorption is severely compromised.

5. Neurological Function The brain is extraordinarily rich in cholesterol: approximately 25% of the body’s total cholesterol is found in the central nervous system, despite the brain representing only about 2% of body weight. Cholesterol is critical for the formation of synapses (connections between nerve cells), the maintenance of myelin sheaths that insulate nerve fibers, and the proper functioning of neurotransmitter systems. Some research has suggested potential links between very low cholesterol and adverse neurological or psychiatric outcomes, although this area requires further investigation.

Where Does Cholesterol Come From?

The human body is remarkably self-sufficient when it comes to cholesterol. The liver produces approximately 70–80% of the cholesterol circulating in the bloodstream through a complex biochemical process known as cholesterogenesis. The remaining 20–30% is absorbed from dietary sources, primarily animal products such as meat, dairy, eggs, and seafood.

This is why dietary changes alone often have a relatively modest effect on blood cholesterol levels in many people, and why genetic factors (such as familial hypercholesterolemia) can have such a dramatic influence on circulating cholesterol values.

Understanding What “Low Cholesterol” Means

When we talk about “low cholesterol”, we need to make a crucial distinction, one that is often overlooked in popular discussions:

• Optimally low cholesterol refers to values that are in the lower-normal or therapeutically targeted range, typically achieved through lifestyle changes or medication (such as statins), in an otherwise healthy individual. This is generally considered beneficial, particularly for cardiovascular health.

• Pathologically low cholesterol (hypocholesterolemia) refers to cholesterol levels that are abnormally and spontaneously low, usually as a consequence of an underlying disease process, severe malnutrition, or a rare genetic condition. This is a completely different clinical scenario.

The critical concept to understand is this: very low cholesterol levels, in the absence of cholesterol-lowering treatment, are typically caused by an underlying health problem, not a cause of increased risk in themselves.

This distinction is absolutely central to resolving the apparent paradox. Let us now explore why.

---

The Real Reason Behind the Correlation

To understand why studies sometimes show a correlation between low cholesterol and higher mortality, we need to introduce a concept that is fundamental to medical research: reverse causality, and its close relative, confounding.

Reverse Causality: When the Arrow Points the Wrong Way

The scientific explanation for the observed correlation between low cholesterol and elevated mortality does not lie in cholesterol itself. It lies in the clinical conditions that cause cholesterol to fall in the first place.

Put simply and clearly:

Low cholesterol does not cause disease or death. Rather, it is disease that causes low cholesterol.

This is the concept of reverse causality, the causal arrow runs in the opposite direction from what a naive reading of the data might suggest. Low cholesterol is not the independent variable driving poor outcomes; it is a dependent variable, a consequence, of the underlying pathology.

Let us look at the conditions most commonly responsible for this phenomenon:

1. Advanced Cancer (Malignancy) Malignant tumors, particularly in advanced stages, are associated with a profound metabolic derangement known as cancer cachexia, a syndrome characterized by severe weight loss, muscle wasting, fatigue, and systemic inflammation. A well-documented consequence of advanced malignancy is a significant reduction in total serum cholesterol. The tumor commandeers the body’s lipid resources, and the liver’s capacity to produce cholesterol is compromised by the disease process. Patients with advanced cancer have high short-term mortality, but this is due to the cancer, not to their low cholesterol.

2. Liver Disease (Cirrhosis and Hepatic Failure) The liver is the primary site of cholesterol synthesis. When the liver is severely damaged, as occurs in cirrhosis (often due to chronic alcohol use, viral hepatitis, or non-alcoholic fatty liver disease), hepatic failure, or other serious hepatic conditions, its ability to produce cholesterol is dramatically impaired. Severely low cholesterol is therefore a recognized marker of advanced liver disease and carries a poor prognosis. Again, the prognosis is driven by the liver disease itself.

3. Severe Systemic Infections and Sepsis Systemic infections, particularly those severe enough to cause sepsis (a life-threatening immune response to infection), are associated with marked decreases in circulating cholesterol levels. The inflammatory cytokines released during sepsis suppress cholesterol synthesis and alter lipid metabolism. Given that sepsis carries significant mortality, any dataset that includes septic patients will show an association between low cholesterol and death, but the cholesterol level is a biomarker of severity, not a cause of death.

4. Malnutrition and Cachexia Severe malnutrition, whether due to inadequate food intake, malabsorption syndromes, or chronic illness, leads to a global reduction in lipid synthesis, including cholesterol. Malnourished individuals have high mortality from numerous causes. Their low cholesterol is a reflection of their nutritional and metabolic state, not an independent risk factor.

5. Hyperthyroidism Excessive thyroid hormone levels accelerate the clearance of LDL cholesterol from the bloodstream, often producing very low total cholesterol values. Severe, untreated hyperthyroidism can have serious cardiovascular consequences (such as atrial fibrillation and heart failure), which again contribute to mortality independently of the cholesterol level.

6. Rare Genetic Conditions Conditions such as abetalipoproteinemia or hypobetalipoproteinemia, rare inherited disorders affecting lipoprotein metabolism, can result in extremely low cholesterol levels and are associated with a range of serious health consequences. These are, however, vanishingly rare in the general population.

Confounding: The Statistical Ghost in the Machine

The second key concept is confounding. In epidemiological research, a confounding variable is one that is associated with both the exposure (in this case, low cholesterol) and the outcome (mortality), and which, if not properly accounted for, can distort the apparent relationship between the two.

In observational studies of cholesterol and mortality, the confounding variables are precisely the serious diseases listed above. An older patient with advanced lung cancer, cirrhosis, and malnutrition will almost certainly have low cholesterol and will also have a high probability of dying in the near term. If researchers simply look at the raw data and see that “people with low cholesterol die more often”, they may conclude that low cholesterol is dangerous. But this conclusion is fundamentally flawed, because it fails to account for the fact that these patients have low cholesterol because they are severely ill.

The technical term for this specific form of confounding in longitudinal studies is the “sick quitter” effect or, more broadly, “reverse causation bias”. It is well recognized in the epidemiological literature and has been extensively discussed in the context of studies on cholesterol, BMI, blood pressure, and numerous other biomarkers.

The Analogy of Fever

To make this concept more intuitive, consider the following analogy:

Imagine that an observational study finds that patients admitted to hospital with high fever have a higher mortality rate than those with normal temperature. Would we conclude that high fever causes death, and therefore we should never treat fever? Of course not. We understand intuitively that the fever is a symptom of a serious underlying condition, pneumonia, meningitis, or sepsis, and that it is the underlying condition, not the fever itself, that drives mortality.

The same logic applies, precisely and exactly, to the association between low cholesterol and mortality in observational data. The low cholesterol is the “fever”, a sign that something is wrong, not the cause of the problem itself.

Why This Matters for Patients

Understanding this distinction is not merely academic. It has real implications for how patients interpret their cholesterol results and medical advice:

• A patient who is otherwise healthy and has low cholesterol due to a plant-based diet, exercise, and genetic factors is not at elevated risk from their low cholesterol.
• A patient who is found to have unexpectedly and spontaneously very low cholesterol, particularly if accompanied by weight loss, fatigue, or other symptoms, should be investigated for underlying causes, not reassured that their cholesterol is “fine”.
• A patient who is taking statins or other lipid-lowering medications and achieves very low cholesterol values under medical supervision is benefiting from that reduction, not being harmed by it.

---

Scientific Evidence from Clinical Trials

While observational epidemiology tells us about associations in real-world populations, randomized controlled clinical trials (RCTs) represent the gold standard of medical evidence. They allow us to test causal hypotheses directly, by randomly assigning patients to receive (or not receive) a treatment, and observing what happens. This design eliminates most of the confounding that plagues observational studies.

When it comes to cholesterol and mortality, the evidence from large-scale RCTs is not just reassuring, it is definitive, consistent, and profoundly important.

The Cholesterol Treatment Trialists’ (CTT) Meta-Analysis

The most comprehensive and authoritative analysis of cholesterol-lowering therapy comes from the Cholesterol Treatment Trialists’ (CTT) Collaboration, which has pooled data from over 170,000 participants across 27 major randomized trials of statin therapy. Their landmark meta-analysis, demonstrated several critical findings:

• Every 1 mmol/L reduction in LDL cholesterol (“bad cholesterol”) was associated with a 22% relative reduction in the risk of major cardiovascular events, including heart attacks, strokes, and the need for revascularization procedures.
• Total mortality was significantly reduced, meaning that people who lowered their cholesterol with statins were less likely to die from any cause, not just cardiovascular causes.
• There was no significant increase in non-cardiovascular mortality, including cancer mortality, even when cholesterol was reduced to very low levels. This finding directly refutes the concern, sometimes voiced by cholesterol skeptics, that lowering cholesterol might increase cancer risk or deaths from other causes.

These are not minor or uncertain findings. They are based on some of the largest and most rigorously conducted clinical trials ever performed in medicine, involving hundreds of thousands of person-years of follow-up. The statistical power is immense, and the consistency across different populations, different statin drugs, and different baseline cholesterol levels is remarkable.

IMPROVE-IT: Lowering LDL Further with Non-Statin Therapy

The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) added ezetimibe, a non-statin cholesterol-lowering drug, to statin therapy in over 18,000 patients who had recently experienced an acute coronary syndrome (heart attack or unstable angina). The combination reduced LDL cholesterol to median levels of approximately 1.4 mmol/L (53 mg/dL), very low by any standard.

The result? Patients who achieved these very low LDL levels had fewer cardiovascular events and no increase in non-cardiovascular harm, compared to those on statin alone with modestly higher LDL levels. This confirmed that “lower is better” for LDL in high-risk patients, and that artificially lowering cholesterol to very low levels through medication is safe.

FOURIER and ODYSSEY: The PCSK9 Inhibitor Trials

The most dramatic evidence for the safety and benefit of very low LDL cholesterol comes from the clinical trials of PCSK9 inhibitors: a new class of powerful injectable medications (evolocumab and alirocumab) that can reduce LDL cholesterol by 50–60% on top of statin therapy, often driving LDL below 0.5 mmol/L (20 mg/dL).

The FOURIER trial (27,564 patients) and the ODYSSEY OUTCOMES trial (18,924 patients) both demonstrated:

• Significant reductions in cardiovascular events, including heart attacks, strokes, cardiovascular death, with very low achieved LDL levels.
• No increase in non-cardiovascular mortality, including no increase in cancer, neurological events, or other serious adverse events, even at the most extremely low cholesterol levels recorded.
• No evidence of harm from very low cholesterol per se.

These findings are remarkable, because they essentially constituted a real-world human experiment in the consequences of extremely low LDL cholesterol, achieved not by disease, but by medical treatment. And the results were uniformly positive.

Mendelian Randomization Studies

An additional layer of evidence comes from Mendelian randomization studies: a sophisticated epidemiological technique that uses naturally occurring genetic variants as proxies for lifelong exposure to lower (or higher) cholesterol levels. Because genetic variants are assigned randomly at conception (analogous to the random allocation in a clinical trial), Mendelian randomization studies are much less susceptible to confounding than conventional observational epidemiology.

Multiple Mendelian randomization studies have consistently shown that individuals who are genetically predisposed to have lower LDL cholesterol throughout their lives have lower rates of cardiovascular disease, and no increased risk from non-cardiovascular causes. This provides powerful causal evidence that low LDL is genuinely protective, not harmful.

What the Evidence Tells Us About the Paradox

Taken together, this body of evidence from clinical trials and Mendelian randomization studies provides the definitive answer to the apparent paradox:

• When cholesterol is intentionally lowered through medication or lifestyle in otherwise well people, it is beneficial and safe, associated with lower cardiovascular mortality and lower overall mortality.
• The correlation between spontaneously low cholesterol and higher mortality seen in observational studies is driven entirely by the underlying serious diseases that cause cholesterol to fall, not by the low cholesterol itself.
• There is no causal mechanism by which medically optimized low cholesterol causes harm in otherwise healthy individuals.

The “low cholesterol is dangerous” myth has been definitively and repeatedly debunked by the highest quality evidence available in modern medicine.

---

Frequently Asked Questions

Patients often arrive at their doctor’s office with questions and concerns shaped by things they have read online or heard from friends. Here are some of the most common questions about low cholesterol and what the evidence says.

Is there such a thing as “too low” for cholesterol?

For practical clinical purposes, the answer is nuanced. In healthy individuals on cholesterol-lowering therapy, there is currently no established lower threshold below which LDL becomes harmful. The major clinical trials have driven LDL to extraordinarily low levels without identifying a floor below which risk begins to rise again.

However, spontaneously very low cholesterol, not caused by medication, particularly when it is new or accompanied by other symptoms, should be investigated. It may be a sign of a serious underlying condition that needs to be identified and treated.

Can low cholesterol cause depression or mental health problems?

This is a question that has received some attention in the literature, with a handful of older observational studies suggesting a possible link between low cholesterol and depression, anxiety, or even suicidality. However, the evidence is inconsistent, and the large-scale clinical trials of statin therapy, which deliberately lower cholesterol in tens of thousands of patients, have not shown an increased risk of psychiatric adverse events.

Again, if a correlation exists in observational data, it may reflect the fact that individuals with serious illnesses (including depression) tend to have lower cholesterol due to poor appetite, weight loss, and metabolic changes, rather than low cholesterol causing the mental health problem.

Should I be worried if my cholesterol is low naturally?

If you have naturally low cholesterol because you eat a healthy diet, exercise regularly, and are otherwise in good health, there is no cause for concern. This is an enviable metabolic profile. Epidemiological studies of populations with chronically low cholesterol, such as certain Asian and African populations, have confirmed lower rates of cardiovascular disease without apparent excess harm from other causes.

Do statins cause cancer by lowering cholesterol too much?

This concern has been raised periodically, based largely on misinterpretations of observational data. However, the large-scale randomized clinical trials, involving hundreds of thousands of patients followed for years, have not found any increase in cancer risk with statin therapy or with achieving very low LDL levels. Multiple systematic reviews and meta-analyses have confirmed this finding. The concern is not supported by the evidence.

What is considered a normal cholesterol level?

Reference ranges vary slightly by laboratory and by clinical context, but in general:

• Total cholesterol: below 200 mg/dL (5.2 mmol/L) is considered desirable.
• LDL cholesterol (“bad cholesterol”): below 100 mg/dL (2.6 mmol/L) is optimal for most people; below 70 mg/dL (1.8 mmol/L) is recommended for those at high cardiovascular risk; even lower targets (below 55 mg/dL or 1.4 mmol/L) are now recommended for very high-risk patients.
• HDL cholesterol (“good cholesterol”): above 40 mg/dL (1.0 mmol/L) for men and above 50 mg/dL (1.3 mmol/L) for women is generally considered protective.
• Triglycerides: below 150 mg/dL (1.7 mmol/L) is desirable.

These thresholds are used as guides; individual targets are best determined by a physician who considers the whole clinical picture.

What diseases can cause low cholesterol?

As discussed in detail above, the main conditions associated with acquired low cholesterol include:

• Advanced malignancy (cancer)
• Severe liver disease (cirrhosis, hepatic failure)
• Systemic infections and sepsis
• Severe malnutrition or malabsorption
• Hyperthyroidism
• Inflammatory bowel disease
• Rare genetic lipoprotein disorders

If you experience unexplained, new-onset low cholesterol, particularly accompanied by other symptoms such as unintentional weight loss, fatigue, jaundice, or persistent fever, it is important to seek medical evaluation promptly.

---

The Broader Context: Cholesterol Denialism and Health Misinformation

It is worth briefly addressing the broader cultural context in which the “low cholesterol is dangerous” myth has flourished. In recent years, a wave of cholesterol skepticism has emerged, partly fueled by popular books, documentaries, and social media influencers who challenge mainstream cardiovascular medicine. Some argue that LDL cholesterol has been unfairly demonized, that statins are ineffective or harmful, and that the lipid hypothesis of cardiovascular disease is fundamentally flawed.

While healthy scientific skepticism is always appropriate, and while there are genuine debates within cardiology about nuances of cholesterol management, the core evidence linking elevated LDL cholesterol to cardiovascular risk, and supporting the benefits of cholesterol-lowering therapy, is among the most robustly established in all of medicine. The claim that low cholesterol is dangerous, derived from a misreading of observational epidemiology, has been a useful rhetorical tool for cholesterol skeptics. But as we have seen, it does not withstand scrutiny.

Patients deserve access to accurate, evidence-based information about their health. The science is clear: for people at elevated cardiovascular risk, achieving lower LDL cholesterol, whether through lifestyle modification, medication, or both, reduces the risk of heart attack, stroke, and death. The apparent paradox of low cholesterol and mortality is a statistical artifact, explained entirely by reverse causality and confounding, and it disappears when properly controlled clinical trial data are examined.

---

Conclusions

The correlation between low cholesterol levels and elevated mortality, observed in some epidemiological studies, is not a causal relationship. It does not mean that low cholesterol causes death or disease. On the contrary, the mechanism is precisely the opposite:

It is serious underlying disease that causes cholesterol to fall, not low cholesterol that causes the disease.

Here’s a concise synthesis of those points:

1. Cholesterol is vital: It’s required for cell membranes, steroid hormones, bile acids, vitamin D, and nervous system function. Low cholesterol per se is not harmful.

2. Spontaneous low cholesterol signals underlying disease: Unexpectedly low levels often reflect serious conditions such as advanced cancer, liver failure, sepsis, or severe malnutrition. The cholesterol itself is a marker, not a cause, of poor outcomes.

3. Observational associations can mislead: Studies linking low cholesterol to higher mortality are usually confounded by reverse causality, illness lowers cholesterol, not the other way around.

4. Intentional LDL reduction is beneficial: Randomized trials and genetic studies show that lowering LDL cholesterol through statins or other therapies reduces cardiovascular events and mortality without causing non-cardiovascular harm, even at very low cholesterol levels.

5. There is no established “floor” below which medically optimized LDL cholesterol becomes harmful. Current evidence supports the principle that “lower is better” for LDL in people at elevated cardiovascular risk.

6. The “low cholesterol is dangerous” narrative, while superficially compelling, is a myth that arises from misinterpretation of observational data. It is not supported by the causal evidence from clinical trials.

If you’re concerned about your cholesterol levels (whether high, low, or borderline), the key step is to discuss them with a qualified healthcare professional. Cholesterol results only make sense when interpreted alongside your overall health, medical history, and cardiovascular risk profile.

Management is highly individual, and what is appropriate for one person may not be for another, so clinical context is essential.

Ultimately, the science is reassuring: protecting and optimizing your cardiovascular health through evidence-based cholesterol management is one of the most powerful tools available to reduce your risk of cardiovascular diseases, heart attack, and stroke, and to live a longer, healthier life.

---

References and Sources

• Cholesterol Treatment Trialists’ (CTT) Collaboration. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials”. The Lancet, 2010. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)61350-5/fulltext
• Crosby J, et al. “Mendelian randomization of blood lipids for coronary heart disease”. European Heart Journal, 2015; 36(22):1382–1388.
• Sabatine MS, et al. “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease (FOURIER)”. New England Journal of Medicine, 2017; 376:1713–1722.
• Schwartz GG, et al. “Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome (ODYSSEY OUTCOMES)”. New England Journal of Medicine, 2018; 379:2097–2107.
• Cannon CP, et al. “Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (IMPROVE-IT)”. New England Journal of Medicine, 2015; 372:2387–2397.
• Ravnskov U, et al. “Lack of an association or an inverse association between low-density-lipoprotein cholesterol and mortality in the elderly: a systematic review”. BMJ Open, 2016; 6:e010401.
• Pirillo A, Catapano AL, Norata GD. “Biological Consequences of Dysfunctional HDL”. Current Medicinal Chemistry, 2019.
• Carlson LA. “Acquired low cholesterol: diagnosis and relevance”. Current Opinion in Lipidology, 2018; 29(4):301–306. https://journals.lww.com/co-lipidology/abstract/2018/08000/acquired_low_cholesterol__diagnosis_and_relevance.8.aspx
• Mach F, et al. “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk”. European Heart Journal, 2020; 41(1):111–188.
• Anderson TJ, et al. “2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult”. Canadian Journal of Cardiology, 2016; 32(11):1263–1282.